N-Acetyl Cysteine (Nac) for Ocd Support

Research suggests that NAC shows promise as an adjunctive treatment for OCD, with multiple meta-analyses and systematic reviews finding positive effects on standardized symptom scores, particularly when added to conventional therapies in cases of moderate-to-severe or treatment-resistant OCD. The proposed mechanisms center on NAC's ability to modulate glutamate signaling and reduce neuroinflammation, both of which have been implicated in OCD pathophysiology, and international expert panels have included NAC among nutraceuticals with meaningful clinical evidence for obsessive-compulsive and related disorders such as trichotillomania and skin picking. However, the evidence is not uniformly strong — some systematic reviews characterize the findings as mixed, a 2023 augmentation review concluded that other agents such as lamotrigine, memantine, and aripiprazole currently have stronger support, and a review focusing on children and adolescents found inconsistent results across trials. Overall, the body of evidence — drawn primarily from RCTs, meta-analyses, and systematic reviews — is encouraging but still developing, and limitations including small sample sizes and variability across study designs mean that definitive conclusions remain premature.